Adverse events of thiopurine immunomodulators in patients with inflammatory bowel disease.
暂无分享,去创建一个
[1] H. Sokol,et al. Incidence of benign upper respiratory tract infections, HSV and HPV cutaneous infections in inflammatory bowel disease patients treated with azathioprine , 2009, Alimentary pharmacology & therapeutics.
[2] C. Girelli,et al. The use of thiopurines for the treatment of inflammatory bowel diseases in clinical practice. , 2008, Digestive and liver disease : official journal of the Italian Society of Gastroenterology and the Italian Association for the Study of the Liver.
[3] J. Gisbert,et al. Acute pancreatitis in inflammatory bowel disease, with special reference to azathioprine‐induced pancreatitis , 2008, Alimentary pharmacology & therapeutics.
[4] J. Gisbert,et al. Thiopurine-Induced Myelotoxicity in Patients With Inflammatory Bowel Disease: A Review , 2008, The American Journal of Gastroenterology.
[5] M. De Vos,et al. Nodular regenerative hyperplasia in patients with inflammatory bowel disease treated with azathioprine , 2007, Gut.
[6] J. Mate,et al. Liver injury in inflammatory bowel disease: Long‐term follow‐up study of 786 patients , 2007, Inflammatory bowel diseases.
[7] J. Mate,et al. Thiopurine-Induced Liver Injury in Patients With Inflammatory Bowel Disease: A Systematic Review , 2007, The American Journal of Gastroenterology.
[8] J. Mate,et al. Thiopurine Methyltransferase Activity in Spain: A Study of 14,545 Patients , 2007, Digestive Diseases and Sciences.
[9] S. Schoenberg,et al. Nodular regenerative hyperplasia: a reversible entity associated with azathioprine therapy. , 2006, European journal of gastroenterology & hepatology.
[10] W. Tremaine,et al. American Gastroenterological Association Institute technical review on corticosteroids, immunomodulators, and infliximab in inflammatory bowel disease. , 2006, Gastroenterology.
[11] F. Dasí,et al. Incidence, risk factors and clinical course of thiopurine‐induced liver injury in patients with inflammatory bowel disease , 2005, Alimentary pharmacology & therapeutics.
[12] J. Satsangi,et al. Toward an integrated clinical, molecular and serological classification of inflammatory bowel disease: report of a Working Party of the 2005 Montreal World Congress of Gastroenterology. , 2005, Canadian journal of gastroenterology = Journal canadien de gastroenterologie.
[13] Wolfgang Schima,et al. A multicenter assessment of liver toxicity by MRI and biopsy in IBD patients on 6-thioguanine. , 2005, Journal of hepatology.
[14] M. Gassull,et al. 6-Mercaptopurine in patients with inflammatory bowel disease and previous digestive intolerance of azathioprine , 2005, Scandinavian journal of gastroenterology.
[15] J. J. Homan van der Heide,et al. Increased incidence of azathioprine‐induced pancreatitis in Crohn's disease compared with other diseases , 2004, Alimentary pharmacology & therapeutics.
[16] W. Selby,et al. Use of 6-Mercaptopurine in Patients with Inflammatory Bowel Disease Previously Intolerant of Azathioprine , 2000, Digestive Diseases and Sciences.
[17] B. Korelitz,et al. Cumulative Experience With Short- and Long-Term Toxicity to 6-Mercaptopurine in the Treatment of Crohn's Disease and Ulcerative Colitis , 2003, Journal of clinical gastroenterology.
[18] S. Targan,et al. 6-thioguanine can cause serious liver injury in inflammatory bowel disease patients. , 2003, Gastroenterology.
[19] J. Gisbert,et al. Terapia individualizada con azatioprina o 6-mercaptopurina mediante monitorización de la actividad de la tiopurina metiltransferasa (TPMT) , 2002 .
[20] J. Mate,et al. [Individualized therapy with azathioprine or 6-mercaptopurine by monitoring thiopurine methyl-transferase (TPMT) activity]. , 2002, Revista clinica espanola.
[21] V. Garrigues,et al. Adverse effects of azathioprine in the treatment of inflammatory bowel disease. , 2001, Revista espanola de enfermedades digestivas : organo oficial de la Sociedad Espanola de Patologia Digestiva.
[22] S. Krähenbühl,et al. Veno-occlusive disease, nodular regenerative hyperplasia and hepatocellular carcinoma after azathioprine treatment in a patient with ulcerative colitis. , 2001, European journal of gastroenterology & hepatology.
[23] G. Mazzacca,et al. Hepatitis related to cytomegalovirus infection in two patients with Crohn's disease treated with azathioprine. , 2000, Digestive and liver disease : official journal of the Italian Society of Gastroenterology and the Italian Association for the Study of the Liver.
[24] G. Lichtenstein,et al. Azathioprine or 6-mercaptopurine for inflammatory bowel disease: do risks outweigh benefits? , 2000, Digestive and liver disease : official journal of the Italian Society of Gastroenterology and the Italian Association for the Study of the Liver.
[25] I. Arnott,et al. Portal hypertension in the presence of minimal liver damage in Crohn's disease on long-term azathioprine: possible endothelial cell injury. , 2000, European journal of gastroenterology & hepatology.
[26] B. Korelitz,et al. Allergic reactions to 6-mercaptopurine during treatment of inflammatory bowel disease. , 1999, Journal of clinical gastroenterology.
[27] B. Kirschner,et al. Safety of azathioprine and 6-mercaptopurine in pediatric patients with inflammatory bowel disease. , 1998, Gastroenterology.
[28] G. Fick,et al. Azathioprine and 6-Mercaptopurine in Crohn Disease , 1995, Annals of Internal Medicine.
[29] M. Kamm,et al. Bone marrow toxicity caused by azathioprine in inflammatory bowel disease: 27 years of experience. , 1993, Gut.
[30] M. Chevallier,et al. Azathioprine induced liver disease: nodular regenerative hyperplasia of the liver and perivenous fibrosis in a patient treated for multiple sclerosis. , 1991, Gut.
[31] S. Meltzer,et al. 6-Mercaptopurine in the management of inflammatory bowel disease: short- and long-term toxicity. , 1989, Annals of internal medicine.